Importance Treatment of locally advanced non–small cell lung cancer (NSCLC) remains
challenging. The rationale of combining a cyclooxygenase 2 (COX-2) inhibitor with …

Aims Clinical trials have reported conflicting results about whether celecoxib plus
chemotherapy improves outcomes over chemotherapy alone in patients with advanced non …

Intermittent hypoxia within tumor microenvironments causes pro-oxidative stress impairing
oxidative phosphorylation (OxPhos) and increases mitochondrial production of reactive …

Purpose Cyclooxygenase-2 (COX-2) and its enzymatic product prostaglandin E2 (PGE2)
possess tumor-promoting activity, and COX-2 is considered as a candidate for targeted …

Background Due to encouraging pre‐clinical data and supportive observational studies,
there has been growing interest in applying cardiovascular drugs (including aspirin …

Objective (s): Combination chemotherapy is a rational strategy to increase patient response
and tolerability and to decrease adverse effects and drug resistance. Recently, the use of …

Background Adjuvant chemotherapy after the resection of stage IB-IIIA non-small cell lung
cancer (NSCLC) is now the standard of care based on large-scale phase III trials and a meta …

Several preclinical and clinical studies have demonstrated that cyclooxygenase‑2 (COX‑2)
inhibitors are efficient for the treatment of non‑small‑cell lung cancer (NSCLC). However, two …

TO THE EDITOR: Groen et al1 recently reported the results of Nederlandse Vereniging voor
Artsen Longziekten en Tuberculose (NVALT)–4, a prospective trial of celecoxib in addition to …

Purpose This study aimed to measure expression of cyclooxygenase-2 (COX-2) and CD34
in pretreatment tumor biopsies from patients on the RTOG C0128 phase II study, and to …